Adeza to Present at the Bank of America 2006 Health Care Conference; Webcast Scheduled Tuesday, May 16 at 3:00 p.m. ET
12 5월 2006 - 1:18AM
Business Wire
Adeza (NASDAQ:ADZA) today announced that Emory V. Anderson,
president and chief executive officer, will make an investment
community presentation at the Bank of America Health Care
Conference 2006 on Tuesday, May 16 at 3:00 p.m. Eastern Time (noon
Pacific Time). The conference is being held at the Four Seasons
Hotel in Las Vegas. A live audio and slide webcast of the
presentation will be available via the Internet by visiting the
Investors section of the company's Web site at www.adeza.com. An
archived presentation will be available on the Web site for 14
days. Adeza designs, manufactures and markets innovative products
for women's health. Adeza's initial focus is on reproductive
healthcare using its proprietary technologies to predict preterm
birth and assess infertility. Adeza's principal product is a
patented diagnostic test, FullTerm(TM), The Fetal Fibronectin Test,
which utilizes a single-use, disposable cassette and is analyzed on
Adeza's patented TLiIQ(R) System. This product is approved by the
U.S. Food and Drug Administration (FDA) for use in assessing the
risk of preterm birth. Adeza also markets and sells the
E-tegrity(R) Test, an infertility-related test to assess
receptivity of the uterus to embryo implantation in women with
unexplained infertility. In May 2006, Adeza announced the
submission of a New Drug Application (NDA) with the FDA for
Gestiva(TM), a form of a naturally occurring progesterone to
prevent preterm birth in women with a history of preterm delivery.
Adeza's NDA submission includes data from a clinical study
conducted by the National Institutes of Health. More information is
available at www.adeza.com. Adeza cautions you that statements
included in this press release that are not a description of
historical facts may be forward-looking statements. The inclusion
of forward-looking statements should not be regarded as a
representation by Adeza that any of its plans will be achieved.
Actual results may differ materially from those set forth in this
release due to the risks and uncertainties inherent in Adeza's
business including, without limitation, statements about the
expansion of the indications for its products. Further information
about these and other risks is included Adeza's Annual Report on
Form 10-K and other periodic and current reports filed by Adeza
with the Securities Exchange Commission, which are available from
the SEC's Web site (www.sec.gov), and also available on the
Investor Relations section of Adeza's Web site. All forward-looking
statements are qualified in their entirety by this cautionary
statement and Adeza undertakes no obligation to revise or update
this news release to reflect events or circumstances after the date
hereof.
Adeza (NASDAQ:ADZA)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Adeza (NASDAQ:ADZA)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Adeza Biomedical (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Adeza News Articles